Your Health, We Care
Release date: 2026-04-02 16:06:21 Recommended: 12
The efficacy of belumosudil has been validated in two clinical studies involving a total of 186 patients with chronic graft-versus-host disease (GVHD). In the trial named ROCKstar, symptoms of chronic GVHD improved in up to 75% of patients (three out of every four). Such improvements were observed across patients with varying disease severity, including mild, moderate, and severe cases. More specifically, more than half of the patients who achieved improvement noticed effects between week 4 and week 8 after treatment initiation, and nearly all patients who ultimately responded showed efficacy by week 24. This indicates that the drug acts relatively rapidly and sustainably.
Chronic GVHD may affect multiple organs in the body, and belumosudil has demonstrated therapeutic responses across different organs. Clinical studies showed that the drug improved symptoms involving the skin, eyes, oral cavity, joints and muscles, gastrointestinal tract, liver, lungs, and esophagus. This means that belumosudil may provide benefit regardless of the primary site affected by chronic GVHD. In addition, the studies enrolled patients who had previously received multiple lines of therapy (including steroids and other immunosuppressants) with inadequate symptom control, as well as those with lesions in one or more organs; these patients were also found to benefit from treatment.
Beyond direct improvement in GVHD symptoms, several additional positive trends were observed in clinical trials of belumosudil. For instance, some patients experienced a reduction in steroid use during treatment. Meanwhile, in an exploratory analysis, some patients reported improvements in quality of life. It should be noted that these findings are exploratory observational results intended to inform a better understanding of the drug, rather than confirmatory conclusions. Furthermore, in terms of safety, no new cases of cytomegalovirus (CMV) infection were reported in clinical studies, with only one case of recurrent infection—an important safety signal for this immunocompromised patient population.
